AstraZeneca Wins FDA Nod for Bladder Cancer Immunotherapy Imfinzi – Genetic Engineering & Biotechnology News
pharmaphorum |
AstraZeneca Wins FDA Nod for Bladder Cancer Immunotherapy Imfinzi
Genetic Engineering & Biotechnology News AstraZeneca has won FDA approval for its advanced bladder cancer candidate Imfinzi™ (durvalumab), which the pharma giant declared will be the cornerstone of an “extensive” immuno-oncology program across multiple cancer types and stages of disease. FDA Approves Imfinzi Immunotherapy for Bladder Cancer AZ's Imfinzi joins the immunotherapy contest |
